Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease

Small-molecule hepatitis C virus (HCV) NS3 protease inhibitors such as boceprevir (SCH 503034) have been shown to have antiviral activity when they are used as monotherapy and in combination with pegylated alpha interferon and ribavirin in clinical trials. Improvements in inhibitor potency and pharm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tong, X., Arasappan, A., Bennett, F., Chase, R., Feld, B., Guo, Z., Hart, A., Madison, V., Malcolm, B., Pichardo, J., Prongay, A., Ralston, R., Skelton, A., Xia, E., Zhang, R., Njoroge, F. G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2010
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2876368/
https://ncbi.nlm.nih.gov/pubmed/20308381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00135-10
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados